lung-cancer

Incidental lung screening findings predict extrapulmonary cancer risk in the following year.

Low-dose CT lung cancer screening frequently detects incidental findings beyond lung nodules. This study found that significant incidental findings on screening CT were associated with an increased risk of being diagnosed with a non-lung cancer (extrapulmonary cancer) within the following year.

Incidental lung screening findings predict extrapulmonary cancer risk in the following year.

This has important implications for how screening programs should follow up on incidental findings—not just focusing on lung nodule management but also considering whether incidental findings warrant additional evaluation for other cancer types.

The finding supports active surveillance protocols for patients with significant incidental CT findings.

Key Findings

Significant incidental findings on lung CT screening associated with increased extrapulmonary cancer risk
Risk elevation observed within the following year
Incidental findings beyond lung nodules (e.g., vascular, abdominal) may signal occult malignancy
Finding supports active follow-up of significant incidental CT findings
Lung screening programs should have protocols for managing extrapulmonary incidental findings

Implications

Lung cancer screening programs should have structured protocols for evaluating and following up on significant incidental findings beyond lung nodules. Radiologists and referring physicians should communicate incidental findings clearly with actionable guidance.

Caveats

RSS news abstract; limited methodological detail; abstract-only. 'Significant' incidental findings definition not specified. Association does not establish causation. False-positive workup burden needs to be balanced against cancer detection benefit.

Source: MedPage Hematology/Oncology — 2026-03-31

Landmark DCIS trial, CRC microbiome & AML combos

Two themes cut across this week’s 236 posts. The first is de-escalation: researchers are building rigorous evidence that patients can safely do less — skip lymph node surgery, forgo radiotherapy, watch pre-invasive lesions instead of cutting them out. The landmark result here is a randomized trial confirming that active surveillance

Colorectal Cancer Microbiome Discovery Platform

Analysis of 9,000+ patients revealed that only colorectal cancer — not other cancer types — consistently harbors distinct microbial communities, suggesting the gut microbiome has a unique relationship with colorectal carcinogenesis that could be exploited for diagnostics and treatment.

GBM Tumor Microenvironment Drug Target Atlas

Non-cancerous brain support cells were found to promote glioblastoma growth through paracrine signaling, and blocking this communication dramatically slowed tumor growth — revealing that GBM's microenvironment contains targetable vulnerabilities that are being systematically overlooked by drug…

BET Inhibitor Target Selectivity Database

BRD2 and BRD4 have fundamentally distinct functions — BRD2 prepares genes for activation while BRD4 triggers transcription — meaning that pan-BET inhibitors have been disrupting gene regulation in counterproductive ways, and the field now needs selective BRD4 inhibitors.

Incidental lung screening findings predict extrapulmonary cancer risk in the following year.

Key Findings

Implications

Caveats

Read more

Landmark DCIS trial, CRC microbiome & AML combos

Colorectal Cancer Microbiome Discovery Platform

GBM Tumor Microenvironment Drug Target Atlas

BET Inhibitor Target Selectivity Database